Air Pollution (PM2.5) on Accelerated Atherosclerosis: A Montelukast Interventional Study in Modernizing China

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT04762472

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04762472
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Hong Kong SAR China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04762472. Randomized; triple masking; primary purpose prevention. Start 2023-09 (anticipated); primary completion 2024-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Air Pollution (PM2.5) on Accelerated Atherosclerosis: A Montelukast Interventional Study in Modernizing China
Condition
Atherosclerosis, Coronary
Intervention (Drug)
Montelukast Oral Tablet
Intervention (Drug)
Montelukast Placebo Oral Tablet
Lead sponsor
Chinese University of Hong Kong (class: other)
Collaborator
People's Hospital of Chongqing (class: other)
Collaborator
Hong Kong University of Science and Technology (class: other)
Collaborator
Chongqing Medical University (class: other)
Collaborator
University of Sydney (class: other)

Record details

Record id
cardio:ct-nct04762472
Content hash
8af94737bdb0205e42c3c60ceaa815018f62113235cc784d3683a011399e53cd